medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Número 5

<< Anterior Siguiente >>

Ann Hepatol 2012; 11 (5)


Prolonged cholestasis triggered by hepatitis A virus infection and variants of the hepatocanalicular phospholipid and bile salt transporters

Krawczyk M, Grünhage F, Langhirt M, Bohle RM, Lammert F

Idioma: Ingles.
Referencias bibliográficas: 30
Paginas: 710-714
Archivo PDF: 122.66 Kb.


RESUMEN

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Koff RS. Hepatitis A. Lancet 1998; 351: 1643-9.

  2. Ciocca M. Clinical course and consequences of hepatitis A infection. Vaccine 2000; 18(Suppl. 1): S71.

  3. Cuthbert JA. Hepatitis A: old and new. Clin Microbiol Rev 2001; 14: 38-58.

  4. Sagnelli E, Coppola N, Marrocco C, Onofrio M, Scarano F, Marotta A, Scolastico C, et al. HAV replication in acute hepatitis with typical and atypical clinical course. J Med Virol 2003; 71: 1-6.

  5. Glikson M, Galun E, Oren R, Tur-Kaspa R, Shouval D. Relapsing hepatitis A. Review of 14 cases and literature survey. Medicine (Baltimore) 1992; 71: 14-23.

  6. Kullak-Ublick GA, Beuers U, Paumgartner G. Hepatobiliary transport. J Hepatol 2000; 32(Suppl. 1): 3-18.

  7. Stieger B, Geier A. Genetic variations of bile salt transporters as predisposing factors for drug-induced cholestasis, intrahepatic cholestasis of pregnancy and therapeutic response of viral hepatitis. Expert Opin Drug Metab Toxicol 2011; 7: 411-25.

  8. Müllenbach R, Lammert F. An update on genetic analysis of cholestatic liver diseases: digging deeper. Dig Dis 2011; 29: 72-7.

  9. Müllenbach R, Linton KJ, Wiltshire S, Weerasekera N, Chambers J, Elias E, Higgins CF, et al. ABCB4 gene sequence variation in women with intrahepatic cholestasis of pregnancy. J Med Genet 2003; 40: e70.

  10. Stapelbroek JM, van Erpecum KJ, Klomp LW, Houwen RH. Liver disease associated with canalicular transport defects: current and future therapies. J Hepatol 2010; 52: 258-71.

  11. Krawczyk M, Müllenbach R, Weber SN, Zimmer V, Lammert F. Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol 2010; 7: 669-81.

  12. Wasmuth HE, Glantz A, Keppeler H, Simon E, Bartz C, Rath W, Mattsson LA, et al. Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter ABCB4 gene. Gut 2007; 56: 265-70.

  13. Bijleveld CM, Vonk RJ, Kuipers F, Havinga R, Fernandes J. Benign recurrent intrahepatic cholestasis: a long-term follow-up study of two patients. Hepatology 1989; 9: 532-7.

  14. Summerfield JA, Scott J, Berman M, Ghent C, Bloomer JR, Berk PD, Sherlock S. Benign recurrent intrahepatic cholestasis: studies of bilirubin kinetics, bile acids, and cholangiography. Gut 1980; 21: 154-60.

  15. Keitel V, Vogt C, Häussinger D, Kubitz R. Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy. Gastroenterology 2006; 131: 624-9.

  16. Kubitz R, Keitel V, Scheuring S, Kohrer K, Häussinger D. Benign recurrent intrahepatic cholestasis associated with mutations of the bile salt export pump. J Clin Gastroenterol 2006; 40: 171-5.

  17. Lang T, Haberl M, Jung D, Drescher A, Schlagenhaufer R, Keil A, Mornhinweg E, et al. Genetic variability, haplotype structures, and ethnic diversity of hepatic transporters MDR3 (ABCB4) and bile salt export pump (ABCB11). Drug Metab Dispos 2006; 34: 1582-99.

  18. Pauli-Magnus C, Kerb R, Fattinger K, Lang T, Anwald B, Kullak-Ublick GA, Beuers U, et al. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 2004; 39: 779-91.

  19. Van Mil SW, van der Woerd WL, van der Brugge G, Sturm E, Jansen PL, Bull LN, van den Berg IE, et al. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology 2004; 127: 379-84.

  20. Byrne JA, Strautnieks SS, Ihrke G, Pagani F, Knisely AS, Linton KJ, Mieli-Vergani G, et al. Missense mutations and single nucleotide polymorphisms in ABCB11 impair bile salt export pump processing and function or disrupt pre-messenger RNA splicing. Hepatology 2009; 49: 553-67.

  21. Hepatitis A vaccines. Wkly Epidemiol Rec 2000; 75: 38-44.

  22. Gordon SC, Reddy KR, Schiff L, Schiff ER. Prolonged intrahepatic cholestasis secondary to acute hepatitis A. Ann Intern Med 1984; 101: 635-7.

  23. Bornstein JD, Byrd DE, Trotter JF. Relapsing hepatitis A: a case report and review of the literature. J Clin Gastroentero 1999; 28: 355-6.

  24. Grünhage F, Spengler U, Fischer HP, Sauerbruch T. Autoimmune hepatitis—sequel of a relapsing hepatitis A in a 75-year-old woman. Digestion 2004; 70: 187-1.

  25. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-67.

  26. Hofmann AF. Rifampicin and treatment of cholestatic pruritus. Gut 2002; 51: 756-7.

  27. Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, Silbert D, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005; 129: 476-85.

  28. Geiger H, Klepper J, Lux P, Heidland A. Biochemical assessment and clinical evaluation of a bilirubin adsorbent column (BR-350) in critically ill patients with intractable jaundice. Int J Artif Organs 1992; 15: 35-9.

  29. Mertens PR, Schönfelder T, Handt S, Kierdorf H, Marschall H, Busch N, Heintz B, et al. Long-term extracorporeal bilirubin elimination: a case report on cascade resin plasmaperfusion. Blood Purif 1998; 16: 341-8.

  30. Available from: http://www.ncbi.nlm.nih.gov/snp.




2020     |     www.medigraphic.com